FDA Upgrades Vitruvias Thyroid Tablet Recall to Class I Over Potency Concerns

Key points

• On September 22, 2026, the FDA reclassified the Vitruvias Therapeutics recall as Class I, indicating a reasonable probability of serious adverse health consequences or death.
• The recall targets one lot of 30 mg thyroid tablets labeled 'Thyroid Tablets, USP' with an expiration date of September 30, 2026.
• Testing confirmed the tablets could be superpotent, meaning they contain more active ingredient than intended, which may cause an overactive thyroid.
• Symptoms of consuming superpotent thyroid tablets include weight loss, heat intolerance, fatigue, and hypertension.
• Approximately 1,900 units were sold from a total batch of 3,600, distributed nationwide from January 31 to September 30, 2025.
• The affected products can be identified by National Drug Code 69680-166-00 or lot number 504950.

Background

This development follows a series of FDA Class I recalls in 2026 involving food and pharmaceutical products. In August 2026, the agency escalated recalls for eggs, frozen blueberries, and guacamole to the highest risk level due to salmonella and E. coli contamination. The current thyroid recall is distinct as it involves a potency issue rather than microbial contamination, but it shares the same highest-risk classification used for products likely to cause serious harm.

Why it matters

A Class I recall signals the most severe risk level, requiring immediate consumer attention. While no adverse events have been reported yet, the potential for superpotent thyroid medication could lead to significant health issues such as hypertension and weight loss. Patients must verify lot numbers and consult medical professionals before altering their medication regimen to avoid complications from sudden changes in thyroid hormone levels.

What to watch

Consumers should check their medication packaging for the specific lot number 504950 or NDC 69680-166-00. Those with the affected product should contact Vitruvias Therapeutics via email at [email protected] or phone at 256-239-9373 for guidance. Healthcare providers will likely monitor patients for symptoms of overactive thyroid if exposure is confirmed.